Hyperfine enrolls initial patients in NEURO PMR study

Hyperfine (HYPR) announced the enrollment of initial patients in the NEURO PMR study. The NEURO PMR study is the first multi-center, prospective observational study of its kind, comparing portable ultra-low-field MRI and conventional high-field MRI with respect to pathology findings, clinical utility, and patient experience. Conducted with two premier private neurology practices-the DENT Neurologic Institute and Texas Neurology-the study utilizes the latest AI-powered portable MRI technology with advanced image quality. The study has a target enrollment of 100 patients and is expected to conclude by year-end. “Neuroimaging has become a cornerstone of modern neurological care, with neurologists ordering an average of 500 MRIs each year. Yet, in-office imaging remains out of reach for most private practices,” explained Dr. Laszlo Mechtler, Principal Investigator of the study and Chief Medical Officer at the DENT Neurologic Institute. “This study aims to identify the best uses for portable brain MRI technology in a comprehensive neurology practice. The goal is to make advanced imaging more accessible, affordable, and convenient for both patients and healthcare providers.”